These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 33328603)

  • 1. Optimal dosing of cytarabine in induction and post-remission therapy of acute myeloid leukemia.
    Walter RB; Appelbaum FR; Estey EH
    Leukemia; 2021 Feb; 35(2):295-298. PubMed ID: 33328603
    [No Abstract]   [Full Text] [Related]  

  • 2. Cytarabine dose in the consolidation treatment of AML: a systematic review and meta-analysis.
    Magina KN; Pregartner G; Zebisch A; Wölfler A; Neumeister P; Greinix HT; Berghold A; Sill H
    Blood; 2017 Aug; 130(7):946-948. PubMed ID: 28679736
    [No Abstract]   [Full Text] [Related]  

  • 3. High-dose cytarabine as salvage therapy for relapsed or refractory acute myeloid leukemia--is more better or more of the same?
    Wolach O; Itchaki G; Bar-Natan M; Yeshurun M; Ram R; Herscovici C; Shpilberg O; Douer D; Tallman MS; Raanani P
    Hematol Oncol; 2016 Mar; 34(1):28-35. PubMed ID: 25689584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sense and nonsense of high-dose cytarabine for acute myeloid leukemia.
    Löwenberg B
    Blood; 2013 Jan; 121(1):26-8. PubMed ID: 23287624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimal dose and schedule of consolidation in AML: is there a standard?
    Schiffer CA
    Best Pract Res Clin Haematol; 2014; 27(3-4):259-64. PubMed ID: 25455275
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Favorable effect of priming with granulocyte colony-stimulating factor in remission induction of acute myeloid leukemia restricted to dose escalation of cytarabine.
    Pabst T; Vellenga E; van Putten W; Schouten HC; Graux C; Vekemans MC; Biemond B; Sonneveld P; Passweg J; Verdonck L; Legdeur MC; Theobald M; Jacky E; Bargetzi M; Maertens J; Ossenkoppele GJ; Löwenberg B; ; ;
    Blood; 2012 Jun; 119(23):5367-73. PubMed ID: 22422824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low dose cytosine arabinoside in the treatment of acute non-lymphoblastic leukemia.
    Insiripong S; Thaisamakr S
    J Med Assoc Thai; 1996 Sep; 79(9):568-71. PubMed ID: 8996985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered.
    Byrd JC; Dodge RK; Carroll A; Baer MR; Edwards C; Stamberg J; Qumsiyeh M; Moore JO; Mayer RJ; Davey F; Schiffer CA; Bloomfield CD
    J Clin Oncol; 1999 Dec; 17(12):3767-75. PubMed ID: 10577848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High dose ara-C combined with autologous peripheral blood stem cell transplantation in the treatment of acute myelogenous leukemia: the question is still not answered.
    Bruserud O; Ernst P
    Stem Cells; 2000; 18(6):459-60. PubMed ID: 11072036
    [No Abstract]   [Full Text] [Related]  

  • 10. Relapse of acute myeloid leukemia as isolated bilateral testicular granulocytic sarcoma in an adult.
    Ghadiany M; Attarian H; Hajifathali A; Khosravi A; Molanaee S
    Urol J; 2008; 5(2):132-4; discussion 134-5. PubMed ID: 18592470
    [No Abstract]   [Full Text] [Related]  

  • 11. [Observation and care in high-dose cytarabine treatment of acute myelogenous leukemia].
    Xi YR; Tu YL; Zhao XH
    Zhonghua Hu Li Za Zhi; 1996 Nov; 31(11):653-5. PubMed ID: 9304928
    [No Abstract]   [Full Text] [Related]  

  • 12. An inexpensive way to treat elderly patients with high-risk MDS or AML.
    Kuendgen A
    Leuk Res; 2011 Aug; 35(8):985-6. PubMed ID: 21561661
    [No Abstract]   [Full Text] [Related]  

  • 13. Intermediate dose cytarabine improves survival and relapse-free rate compared with standard-dose cytarabine as post-remission treatment for acute myeloid leukemia: A retrospection study.
    Ye L; Gao L; Cheng Q; Guo F; He L; Yuan T; Zhu M; Ma Y; Pan M; Chu X; Ding M; Yu G
    Medicine (Baltimore); 2021 Jan; 100(3):e24273. PubMed ID: 33546048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction therapy for elderly patients with acute myeloid leukemia.
    Martin MG; Abboud CN
    Blood Rev; 2008 Nov; 22(6):311-20. PubMed ID: 18539373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytarabine dose for acute myeloid leukemia.
    Mori J; Tsubokura M; Kami M
    N Engl J Med; 2011 Jun; 364(22):2166-7; author reply 2168-9. PubMed ID: 21631342
    [No Abstract]   [Full Text] [Related]  

  • 16. A microarray study of altered gene expression after cytarabine resistance in acute myeloid leukemia.
    Yin B; Tsai ML; Hasz DE; Rathe SK; Le Beau MM; Largaespada DA
    Leukemia; 2007 May; 21(5):1093-7. PubMed ID: 17301810
    [No Abstract]   [Full Text] [Related]  

  • 17. [Treatment for acute myeloid leukemia: introduction].
    Miyawaki S
    Nihon Rinsho; 2007 Jan; 65 Suppl 1():459-68. PubMed ID: 17474448
    [No Abstract]   [Full Text] [Related]  

  • 18. Cytarabine dose for acute myeloid leukemia.
    Mathisen MS
    N Engl J Med; 2011 Jun; 364(22):2167; author reply 2168-9. PubMed ID: 21631341
    [No Abstract]   [Full Text] [Related]  

  • 19. [Petechiae, suffusions and cytarabine-induced erythema in treatment of acute myeloid leukemia].
    Taverna C; Jacky E; Sauter C
    Schweiz Med Wochenschr; 1998 Jul; 128(27-28):1117. PubMed ID: 9691347
    [No Abstract]   [Full Text] [Related]  

  • 20. High-dose cytarabine induction for acute myeloid leukemia.
    Shepherd JD; Barnett MJ; Philips GL
    Blood; 1996 Jul; 88(2):754-5. PubMed ID: 8695826
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.